These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38290229)

  • 21. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
    Li L; Wang Z; Li R; Luo S; Sun X
    Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.
    Lakhani P; Patil A; Majumdar S
    J Ocul Pharmacol Ther; 2019; 35(1):6-22. PubMed ID: 30481082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular Inserts of Voriconazole-Loaded Proniosomal Gels: Formulation, Evaluation and Microbiological Studies.
    El-Emam GA; Girgis GNS; El-Sokkary MMA; El-Azeem Soliman OA; Abd El Gawad AEGH
    Int J Nanomedicine; 2020; 15():7825-7840. PubMed ID: 33116503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro polymyxin activity against clinical multidrug-resistant fungi.
    Yousfi H; Ranque S; Rolain JM; Bittar F
    Antimicrob Resist Infect Control; 2019; 8():66. PubMed ID: 31044071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro synergy of natamycin and voriconazole against clinical isolates of
    Sradhanjali S; Yein B; Sharma S; Das S
    Br J Ophthalmol; 2018 Jan; 102(1):142-145. PubMed ID: 28982951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Galleria mellonella as an alternative in vivo model to study implant-associated fungal infections.
    Mannala GK; Rupp M; Walter N; Scholz KJ; Simon M; Riool M; Alt V
    J Orthop Res; 2023 Nov; 41(11):2547-2559. PubMed ID: 37080929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Effects of Farnesol Alone and in Combination with Antifungal Drugs Against Aspergillus Clinical Isolates.
    Onder S; Oz Y
    Med Mycol J; 2021; 62(1):5-10. PubMed ID: 33642525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.
    Meletiadis J; Pournaras S; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2010 Feb; 54(2):602-9. PubMed ID: 19995928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exogenous fungal endophthalmitis: an analysis of isolates and susceptibilities to antifungal agents over a 20-year period (1990-2010).
    Silva RA; Sridhar J; Miller D; Wykoff CC; Flynn HW
    Am J Ophthalmol; 2015 Feb; 159(2):257-64.e1. PubMed ID: 25449001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    D'agostino M; Tesse N; Lavergne RA; Le Pape P; Frippiat JP; Machouart M; Debourgogne A
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34491156
    [No Abstract]   [Full Text] [Related]  

  • 34. Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
    Shah KB; Wu TG; Wilhelmus KR; Jones DB
    Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.
    Sun CQ; Lalitha P; Prajna NV; Karpagam R; Geetha M; O'Brien KS; Oldenburg CE; Ray KJ; McLeod SD; Acharya NR; Lietman TM;
    Ophthalmology; 2014 Aug; 121(8):1495-500.e1. PubMed ID: 24746358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Necessity to identify the causative agent for appropriate treatment in fungal corneal ulcer: an in vitro study.
    Gupta MK; Chandra A; Prakash P; Tilak R
    J Mycol Med; 2018 Mar; 28(1):201-205. PubMed ID: 29398639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endophthalmitis associated with fungal keratitis and penetrating injuries in North China.
    Liu MY; Zhang L; Yin XL; Sun SY
    Eur J Ophthalmol; 2020 May; 30(3):455-461. PubMed ID: 30832500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and Antifungal Susceptibility of
    Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
    Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voriconazole-Cyclodextrin Supramolecular Ternary Complex-Loaded Ocular Films for Management of Fungal Keratitis.
    Suvarna P; Chaudhari P; Birangal S; Mallela LS; Roy S; Koteshwara A; Aranjani JM; Lewis SA
    Mol Pharm; 2022 Jan; 19(1):258-273. PubMed ID: 34928610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of propyl gallate on the activity of various antifungal drugs against filamentous fungi in vitro].
    Xu Y; Pang GR; Lü XF; Chen ZJ; Sun ST; Song JZ
    Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):309-12. PubMed ID: 16762206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.